They got into a research license agreement with Janssen (Johnson&Johnson) in April for an undisclosed target. Most likely for a type of cancer.
They recently announced several neutralizing SARS-cov-2 antibodies from their human and llama campaign. They will be soon announcing their antibodies discovered on Ligand’s (LGND) OmniAb platform (OmniRat) and also Rabbit antibodies. They’ll have 1600 Covid neutralizing mAbs.
In 2019 they created Talem Therapeutics which gives them the ability to out license their antibodies and partner with Big Pharma or whoever wants them. They already do business with several of big pharmas so the connections and trust are already there. When companies want to use IPAs services the audit process is roughly a year long so the Big Pharmas that are already on board should be very interested in their Covid discoveries.
They collaborated with the NIH for characterization of their antibodies. That should be released in a peer reviewed article in the near future. That will be big news and provide validation to the companies interested in licensing with them.
I don’t think there’s another company with the amount of sars-cov-2 specific antibodies like IPA. They did everything from the ground up and discovered mAbs from Humans, Llamas, Rabbits and OmniRat.
Will be interesting to see what moves they make this summer. They have potential to do several licensing deals (upfront payment+royalties) and also take an antibody cocktail through animal trials themselves.
IPA is also developing a saliva based test with the University of Victoria. A photographer from Bloomberg was there the other day so we should see some media coverage soon.
They also announced a Covid vaccine program that’s being funded by TRANSVAC in Europe. You only get that if your antibodies are good.
There’s so much going on with this company right now so we should be getting a lot of news soon. I’m sure their strategy is to bring in as many licensing deals (upfront payments) as possible which will set them up for future projects in immuno-oncology.
Few more developments and we should be headed to the Nasdaq where the real fun will start.
Nice to have another person on the board.
Recent IPA News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 06:40:14 PM
- ImmunoPrecise Antibodies (IPA) publie ses résultats financiers et les faits saillants de ses activités du premier trimestre de l’exercice 2025 • Business Wire • 09/17/2024 02:13:00 AM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 09/16/2024 08:01:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 01:04:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 01:03:19 PM
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 • Business Wire • 09/16/2024 01:00:00 PM
- U.S. Markets Await Fed Decision and Empire State Report Amid Global Economic Shifts; Oil Prices Rise Slightly • IH Market News • 09/16/2024 10:04:55 AM
- IPA publiera le 16 septembre 2024 ses résultats financiers et les récents faits saillants de ses activités du premier trimestre de l’exercice 2024 • Business Wire • 09/09/2024 09:44:00 PM
- IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 • Business Wire • 09/09/2024 01:11:00 PM
- L'IPA participera à la 26e conférence annuelle mondiale de l'investissement organisée par H.C. Wainwright à New York • Business Wire • 08/26/2024 04:12:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/26/2024 01:41:08 PM
- ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York • Business Wire • 08/26/2024 01:00:00 PM
- ImmunoPrecise Antibodies reçoit un avis de la part du Nasdaq concernant les exigences minimales en matière d'offre • Business Wire • 08/24/2024 07:35:00 AM
- ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements • Business Wire • 08/24/2024 12:00:00 AM
- ImmunoPrecise Antibodies conçoit des anticorps in silico pour des protéines tumorales élusives en utilisant sa technologie LENSai brevetée • Business Wire • 08/19/2024 06:04:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 01:21:46 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/19/2024 04:15:03 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/06/2024 09:16:28 PM
- ImmunoPrecise Antibodies (IPA) publie ses résultats financiers et ses mises à jour commerciales pour le quatrième trimestre et l'exercice 2024 • Business Wire • 07/30/2024 01:05:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/29/2024 12:38:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 12:35:02 PM
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 • Business Wire • 07/29/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/24/2024 01:55:46 AM
- ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 • Business Wire • 07/23/2024 11:30:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM